Pacific Edge Ltd

AU:PEB Australia Diagnostics & Research
Market Cap
$104.45 Million
AU$168.68 Million AUD
Market Cap Rank
#18707 Global
#298 in Australia
Share Price
AU$0.17
Change (1 day)
+3.13%
52-Week Range
AU$0.07 - AU$0.22
All Time High
AU$1.54
Categories
Companies in Australia Diagnostics & Research
About

Pacific Edge Limited, a cancer diagnostics company, engages in development and commercialization of bladder cancer diagnostic and prognostic tests for patients. It operates through two segments, Commercial and Research. The company offers Cxbladder, a genomic urine biomarker test for the detection and surveillance of bladder cancer. It also develops Cxbladder Triage, a frontline diagnostic produc… Read more

Pacific Edge Ltd (PEB) - Net Assets

Latest net assets as of September 2025: AU$26.68 Million AUD

Based on the latest financial reports, Pacific Edge Ltd (PEB) has net assets worth AU$26.68 Million AUD as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$34.38 Million) and total liabilities (AU$7.71 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets AU$26.68 Million
% of Total Assets 77.59%
Annual Growth Rate 17.06%
5-Year Change 3.89%
10-Year Change -12.49%
Growth Volatility 205.39

Pacific Edge Ltd - Net Assets Trend (2005–2025)

This chart illustrates how Pacific Edge Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Pacific Edge Ltd (2005–2025)

The table below shows the annual net assets of Pacific Edge Ltd from 2005 to 2025.

Year Net Assets Change
2025-03-31 AU$26.09 Million -56.19%
2024-03-31 AU$59.55 Million -32.65%
2023-03-31 AU$88.41 Million -24.17%
2022-03-31 AU$116.60 Million +364.36%
2021-03-31 AU$25.11 Million +73.12%
2020-03-31 AU$14.50 Million +4.27%
2019-03-31 AU$13.91 Million -16.41%
2018-03-31 AU$16.64 Million -20.11%
2017-03-31 AU$20.83 Million -30.12%
2016-03-31 AU$29.81 Million +178.51%
2015-03-31 AU$10.70 Million -50.86%
2014-03-31 AU$21.78 Million +95.40%
2013-03-31 AU$11.15 Million -36.95%
2012-03-31 AU$17.68 Million +557.01%
2011-03-31 AU$2.69 Million +138.34%
2010-03-31 AU$1.13 Million +338.97%
2009-03-31 AU$257.17K -89.40%
2008-03-31 AU$2.43 Million +620.26%
2007-03-31 AU$336.81K -65.43%
2006-03-31 AU$974.17K -12.82%
2005-03-31 AU$1.12 Million --

Equity Component Analysis

This analysis shows how different components contribute to Pacific Edge Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 26628000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (March 2025)

Component Amount Percentage
Common Stock AU$294.46 Million 1128.84%
Other Comprehensive Income AU$7.85 Million 30.09%
Total Equity AU$26.09 Million 100.00%

Pacific Edge Ltd Competitors by Market Cap

The table below lists competitors of Pacific Edge Ltd ranked by their market capitalization.

Company Market Cap
Gold Reserve Inc
OTCQX:GDRZF
 		$89.70 Million
TAB GIDA
IS:TABGD
 		$89.70 Million
Companhia Brasileira De Distribuicao
PINK:CBDBY
 		$89.70 Million
Complete Solaria, Inc. Common Stock
NASDAQ:CSLR
 		$89.72 Million
Inovio Pharmaceuticals Inc
NASDAQ:INO
 		$89.63 Million
Caravel Minerals Ltd
AU:CVV
 		$89.58 Million
BLOCKCHAIN GRP SA EO-04
F:BC7
 		$89.55 Million
Interlife General Insurance S.A.
AT:INLIF
 		$89.49 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Pacific Edge Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 59,546,495 to 26,085,000, a change of -33,461,495 (-56.2%).
  • Net loss of 29,936,000 reduced equity.
  • Other comprehensive income increased equity by 685,586.
  • Other factors decreased equity by 4,211,081.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income AU$-29.94 Million -114.76%
Other Comprehensive Income AU$685.59K +2.63%
Other Changes AU$-4.21 Million -16.14%
Total Change AU$- -56.19%

Book Value vs Market Value Analysis

This analysis compares Pacific Edge Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 5.13x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has decreased from 5.65x to 5.13x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2005-03-31 AU$0.03 AU$0.17 x
2006-03-31 AU$0.02 AU$0.17 x
2007-03-31 AU$0.00 AU$0.17 x
2008-03-31 AU$0.02 AU$0.17 x
2009-03-31 AU$0.00 AU$0.17 x
2010-03-31 AU$0.01 AU$0.17 x
2011-03-31 AU$0.01 AU$0.17 x
2012-03-31 AU$0.07 AU$0.17 x
2013-03-31 AU$0.03 AU$0.17 x
2014-03-31 AU$0.06 AU$0.17 x
2015-03-31 AU$0.03 AU$0.17 x
2016-03-31 AU$0.08 AU$0.17 x
2017-03-31 AU$0.05 AU$0.17 x
2018-03-31 AU$0.04 AU$0.17 x
2019-03-31 AU$0.03 AU$0.17 x
2020-03-31 AU$0.02 AU$0.17 x
2021-03-31 AU$0.04 AU$0.17 x
2022-03-31 AU$0.15 AU$0.17 x
2023-03-31 AU$0.11 AU$0.17 x
2024-03-31 AU$0.07 AU$0.17 x
2025-03-31 AU$0.03 AU$0.17 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Pacific Edge Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -114.76%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -137.03%
  • • Asset Turnover: 0.59x
  • • Equity Multiplier: 1.42x
  • Recent ROE (-114.76%) is above the historical average (-166.06%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2005 -254.88% -5696.00% 0.04x 1.24x AU$-2.96 Million
2006 -258.36% 0.00% 0.00x 1.33x AU$-2.61 Million
2007 -558.43% 0.00% 0.00x 1.67x AU$-1.91 Million
2008 -79.06% -2339.02% 0.03x 1.31x AU$-2.16 Million
2009 -962.01% -1124.55% 0.25x 3.49x AU$-2.50 Million
2010 -223.93% 0.00% 0.00x 1.60x AU$-2.64 Million
2011 -116.07% -624600.00% 0.00x 1.22x AU$-3.39 Million
2012 -23.07% -2059.60% 0.01x 1.05x AU$-5.85 Million
2013 -62.06% -3800.55% 0.01x 1.10x AU$-8.03 Million
2014 -45.69% -1902.68% 0.02x 1.04x AU$-12.13 Million
2015 -100.25% -564.68% 0.15x 1.18x AU$-11.80 Million
2016 -52.59% -315.07% 0.15x 1.08x AU$-18.66 Million
2017 -100.73% -260.24% 0.34x 1.13x AU$-23.06 Million
2018 -118.05% -577.76% 0.17x 1.18x AU$-21.31 Million
2019 -128.81% -469.43% 0.23x 1.19x AU$-19.31 Million
2020 -130.21% -432.17% 0.23x 1.33x AU$-20.34 Million
2021 -56.65% -158.47% 0.29x 1.24x AU$-16.73 Million
2022 -16.97% -172.90% 0.09x 1.06x AU$-31.45 Million
2023 -30.50% -128.20% 0.22x 1.10x AU$-35.81 Million
2024 -54.07% -127.62% 0.35x 1.20x AU$-38.15 Million
2025 -114.76% -137.03% 0.59x 1.42x AU$-32.54 Million

Industry Comparison

This section compares Pacific Edge Ltd's net assets metrics with peer companies in the Diagnostics & Research industry.

Industry Context

  • Industry: Diagnostics & Research
  • Average net assets among peers: $175,704,840
  • Average return on equity (ROE) among peers: -17.09%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Pacific Edge Ltd (PEB) AU$26.68 Million -254.88% 0.29x $89.67 Million
Australian Clinical Labs Ltd (ACL) $68.99 Million 59.80% 4.31x $217.50 Million
Bcal Diagnostics Ltd (BDX) $6.22 Million -116.40% 0.59x $10.33 Million
Capitol Health Ltd (CAJ) $144.04 Million 0.60% 0.82x $222.66 Million
Cryosite Ltd (CTE) $1.45 Million 126.98% 12.60x $5.03 Million
Genetic Signatures Ltd (GSS) $16.18 Million -10.68% 0.02x $8.20 Million
Healius Ltd (HLS) $1.04 Billion -62.05% 1.87x $208.81 Million
Inoviq Ltd (IIQ) $2.83 Million -115.42% 0.16x $23.33 Million
Microba Life Sciences Ltd (MAP) $32.49 Million -45.98% 0.46x $10.42 Million
Monash Ivf Group Ltd (MVF) $268.44 Million 9.37% 0.33x $116.82 Million